BIOANALYSIS METHOD DEVELOPMENT AND VALIDATION OF SMALL MOLECULES IN PHARMACEUTICAL INDUSTRY: A BIOANALYST REVIEW POINT

  • SATHESHKUMAR S Department of Pharmaceutics, College of Pharmacy, Vinayaka Mission’s College of Pharmacy, Salem, Tamil Nadu, India.
  • MURUGANANTHAM V Department of Pharmaceutics, College of Pharmacy, Vinayaka Mission’s College of Pharmacy, Salem, Tamil Nadu, India.
  • KANAGA SABAPATHI S Department of Bioanalytical, Drug Metabolism and Pharmacokinetics, Anthem Biosciences Private Limited, Bengaluru, Karnataka, India.
  • CHITHRA A Quality Control, Bioanalytical Research Laboratory, Syngene International Limited, Bengaluru, Karnataka, India.

Abstract

The focus of bioanalysis employed for the quantitative determination of an active analyte(s) and their metabolite(s) in the biological matrix such as plasma, serum, blood, cerebrospinal fluid, and tissues. The extraction of analyte and metabolite in the biological fluids is carried out using different separation methods such as protein precipitation, liquid-liquid extraction, and solid phase extraction. Bioanalytical method development and validation in the pharmaceutical industry are to provide an assessment and interpretation of pharmacokinetics, pharmacodynamics, toxicokinetics, bioavailability/bioequivalence, and therapeutic drug monitoring relationships. This review paper aims to provide a simple and accurate scientific background to improve the quality for development and validation of a bioanalytical method for small molecules with industrial technique as per regulatory agency requirements (United States Food and Drug Administration, EMEA, International Council for Harmonisation and ANVISA).

Keywords: Matrix factor, Recovery, Stability, Quality control, Liquid chromatography-mass spectrometry

References

1. Wenkui L, Jie Z, Francis LS. Handbook of LC-MS Bioanalysis. New Jersey: John Wiley & Sons; 2013.
2. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res 2000;17:1551-7.
3. Alan XU, Madden TL. LC-MS in Drug Bio-Analysis. Boston: Springer; 2012.
4. Venn RF. Principles and Practice of Bio-Analysis. London: Taylor & Francis; 2000.
5. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Pharm Res 1992;9:588-92.
6. Kadian N, Raju KS, Rashid M, Malik MY, Taneja I, Wahajuddin M. Comparative assessment of bio-analytical method validation guidelines for pharmaceutical industry. J Pharm Biomed 2016;126:83-97.
7. F.D.A. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center of Veterinary Medicine (CVM) Guidance for Industry: Bio-Analytical Method Validation; 2018.
8. F.D.A. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center of Veterinary Medicine (CVM) Guidance for Industry: Bio-Analytical Method Validation; 2013.
9. F.D.A. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center of Veterinary Medicine (CVM) Guidance for Industry: Bio-Analytical Method Validation; 2001.
10. ANVISA, Agencia Nacional de Vigilancia Sanitaria, Guide for Validation of Analytical and Bio-Analytical Methods Resolution-RE No. 899; 2003.
11. ANVISA, Ministry of Health, National Health Surveillance Agency, Resolution-RDC No. 27; 2012.
12. EMA, Committee for Medicinal Product for Human Use Guideline on Bio-Analytical Method Validation; 2011.
13. MHLW, Guideline on Bio-Analytical Method Validation in Pharmaceutical Development; 2013.
14. ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: Bio-Analytical Method Validation M10; 2019.
15. Niazi SK. Handbook of Bioequivalence Testing. New York: Informa Healthcare; 2007.
16. Rifai N, Horvath AR, Wittwer CT, Hoofnagle A, editors. Principles and Applications of Clinical Mass Spectrometry. 5th ed. Netherlands: Elsevier; 2018. p. 67-91.
17. Snyder LR, Kirkland JJ, Glajch JL. Practical HPLC Method Development. 2nd ed. United States: John Wiley & Sons; 2001.
18. Tijare LK, Rangari NT, Mahajan UN. A review on bioanalytical method development and validation. Asian J Pharm Clin Re 2016;9:6-10.
19. Sargent M. Guide to Achieving Reliable Quantitative LC-MS Measurements, RSC Analytical Methods Committee; 2013.
20. Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. Pharm Methods 2010;1:25-38.
21. Mano Y. Method validation studies and an inter-laboratory cross validation study of lenvatinib assay in human plasma using LC-MS MS. Pract Lab Med 2018;12:e00103.
22. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. AAPS J 2007;9:E260-7.
23. Satheshkumar S, Muruganantham V. A simple and rugged bio-analytical method development and validation of brivudine in human plasma by using high-performance liquid chromatography. Int J Pharm Pharm Sci 2010;12:45-50.
24. Dadgar D, Burnett PE. Issues in evaluation of bioanalytical method selectivity and drug stability. J Pharm Biomed 1995;14:23-31.
25. Ingelse B, Barroso B, Gray N, Jakob-Rodamer V, Kingsley C, Sykora C, et al. European bioanalysis forum: Recommendation on dealing with hemolyzed and hyperlipidemic matrices. Bioanalysis 2014;6:3113-20.
26. Scientific Working Group for Forensic Toxicology. Scientific working group for forensic toxicology (SWGTOX) standard practices for method validation in forensic toxicology. J Anal Toxicol 2013;37:452-74.
27. International Conference on Harmonization (ICH). Validation of Analytical Methods: Methodology, International Conference on Harmonization Q2 B; 1996.
28. Thompson M, Ellison SL, Wood R. Harmonized guidelines for single laboratory validation of method of analysis. Pure Appl Chem 2008;74:835-55.
29. Saudagar RB, Thete PG. Bioanalytical method validation: A concise review. Asian J Pharm Sci 2018;8:107-14.
30. Kollipara S, Bende G, Agarwal N, Varshney B, Paliwal J. International guidelines for bioanalytical method validation: A comparison and discussion on current scenario. Chromatographia 2011;73:201-17.
31. Hall TG, Smukste I, Bresciano KR, Wang Y, McKearn D, Savage RE. Identifying and overcoming matrix effects in drug discovery and development. In: Prasain JK, editor. Tandem Mass Spectrometry- Applications and Principles. London: Intech Open; 2012. p. 389-421.
32. Braggio S, Barnaby RJ, Grosi P, Cugola. A strategy for validation of bioanalytical methods. J Pharm Biomed 1996;14:375-88.
33. Bansal S, DeStefano A. Key elements of bio-analytical method validation for small molecules. AAPS J 2007;9:109-14.
34. Boer T, Wieling J. Incurred sample accuracy assessment: Design of experiments based on standard addition. Bioanalysis 2011;3:983-92.
35. Wood R. How to validate analytical methods. Trends Analyt Chem 2005;18:624-32.
36. McDowall RD. The role of laboratory information management systems LIMS in analytical method validation. Anal Chim Acta 2007;54:149-58.
37. Heyden YV, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal 2001;24:723-53.
38. Puluido A, Ruusanches I, Boque R, Rius FX. Uncertainty of results in routine qualitative analysis in analytical chemistry. J Pharm Biomed Anal 2005;22:647-54.
39. Jhang JS, Chang CC, Fink DJ, Kroll MH. Evaluation of linearity in the clinical laboratory. Arch Pathol Lab Med 2004;128:44-8.
40. Mark H. Application of an improved procedure for testing the linearity of analytical methods to pharmaceutical analysis. J Pharm Biomed Anal 2003;33:7-20.
41. Trullols E, Ruisanchez I, Rius FX. Trends in analytical chemistry. J Lab Invest 2003;23:137-45.
42. Valcarcel M, Cardenas S, Gallego M. Sample screening system in analytical chemistry. Trends Analyt Chem 1999;18:685-94.
43. Ye C, Liu J, Ren F, Okafo N. Design of experiment and data analysis by JMP (SAS institute) in analytical method validation. J Pharm Biomed Anal 2000;23:581-9.
44. Lindner W, Wainer IW. Requirements for initial assay validation and publication in J. Chromatography B. J Chromatogr B Biomed Sci Appl 1998;707:1-2.
45. Penninckx W, Hartmann C, Massart DL, Smeyers-Verbeke J. Validation of the calibration procedure in atomic absorption spectrometric methods. J Anal At Spectrom 1998;11:237-46.
46. Nowatzke W, Woolf E. Best practices during bio-analytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J 2007;9:E117-22.
47. James CA, Breda M, Frigerio E. Bio-analytical method validation: A risk-based approach? J Pharm Biomed Anal 2004;35:887-93.
48. Nakashima K. High-performance liquid chromatography of drug of abuse in biological samples. J Health Sci 2009;51:272-7.
49. Boulanger B, Chiap P, Dewe W, Crommen J, Hubert P. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: Progress and limitations. J Pharm Biomed Anal 2003;32:753-65.
50. Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B Biomed Sci Appl 1997;689:175-80.
51. Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD. Validation of bioanalytical chromatographic methods. J Pharm Biomed Anal 1998;17:193-218.
52. Hubert P, Chiap P, Crommena J, Boulanger B, Chapuzet EN, Laurentie M, et al. The SFSTP guide on the validation of chromatographic methods for drug bio-analysis: From the Washington Conference to the laboratory. Anal Chim Acta 1999;391:135-48.
53. Zhoua S, Songb Q, Tangb Y, Weng N. Critical review of development, validation, and transfer for high throughput bio-analytical LC-MS/MS methods. Curr Pharm Anal 2005;55:3-14.
54. Tabrizi-Fard MA, Fung HL. Reversed-phase high-performance liquid chromatography method for the analysis of nitro-arginine in rat plasma and urine. J Chromatogr B Biomed Appl 1996;679:7-12.
55. Hartmann C, Massart DL, McDowall RD. An analysis of the Washington Conference report on bio-analytical method validation. J Pharm Biomed Anal 1994;12:1337-43.
56. Wieling J, Hendriks G, Tamminga WJ, Hempenius J, Mensink CK, Oosterhuis B, et al. Rational experimental design for bio-analytical methods validation. Illustration using an assay method for total captopril in plasma. J Chromatogr 2006;730:381-94.
57. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW, et al. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm Res 2001;18:1373-83.
58. Kringle R, Hoffman D. Stability methods for assessing stability of compounds in whole blood for clinical bioanalysis. Drug Inf J 2001;35:1261-70.
59. Chiu ML, Lawi W, Snyder ST, Wong PK, Liao JC, Gau V. Matrix effects: A challenge toward automation of molecular analysis. J Assoc Lab Autom 2010;15:233-42.
60. Reid E, Wilson ID. Methodological survey in biochemistry and analysis. In: Analysis for Drug and Metabolites, Including Anti-Infective Agents. Vol. 20. Cambridge, England: Royal Society of Chemistry; 1990. p. 1-57.
61. Kallner A. Quality specifications based on the uncertainty of measurement. Scand J Clin Lab Invest 1999;59:513-6.
62. Rao KR, Kumar KS. Bioanalytical method validation-a quality assurance auditor view point. J Pharm Sci Res 2009;1:1-10.
63. Lang JR, Bolton S. A comprehensive method validation strategy for bio-analytical applications in the pharmaceutical industry. Experimental considerations. J Pharm Biomed Anal 1991;9:357-61.
64. Shah VP. The history of bio-analytical method validation and regulation: Evolution of a guidance document on bio-analytical method validation. AAPS J 2007;9:43-7.
65. Buick AR, Doig MV, Jeal SC, Land GS, McDowall RD. Method validation in the bio-analytical laboratory. J Pharm Biomed Anal 1990;8:629-37.
66. Mark H. Application of improved procedure for testing linearity of analytical method to pharmaceutical analysis. J Pharm Biomed Anal 2003;33:7-20.
67. Wells DA. High throughput bio-analytical sample preparation: Methods and automation strategies. In: Progress in Pharmaceutical and Biomedical Analysis. Vol. 30. Amsterdam, London: Elsevier; 2003. p. 610.
68. Karnes HT, Shiu G, Shah VP. Validation of bio-analytical methods. Pharm Res 1991;8:421-6.
69. Kringle RO. An assessment of the 4-6-20 rule of acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies. Pharm Res 1994;11:556-60.
70. Singh PS, Shah G. Analytical method development and validation. J Pharm Res 2011;4:2330-2.
71. Timm U, Wall M, Dell D. A new approach for dealing with the stability of drugs in biological fluids. J Pharm Sci 1985;74:972-7.
72. Buszewski B, Szultka M. Past, Present, and Future of Solid Phase Extraction: A Review, Crit. Rev. Anal. Chem., 2012;42:198-13.
73. Satheshkumar S, Muruganatham V. Development of validated bio-analytical RP-HPLC method for determination of sofosbuvir in human plasma. Am J Pharm Tech Res 2020;10:82-92.
74. Madhavi S, Rani AP. Bio-analytical method development and validation for the determination of sofosbuvir from human plasma. Int J Pharm Pharm Sci 2017;9:35-41.
75. Vikas PM, Satyanarayana T, Kumar DV, Mounika E, Latha MS, Anusha R, et al. Development and validation of new RP-HPLC method for the determination of sofosbuvir in pure form. World J Pharm Pharm Sci 2016;5:775-81.
76. Mamdouh R, Emad RB, Karim BI. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007 in human plasma: Application to a bioequivalence study. J Pharm Biomed Anal 2015;114:97-104.
77. Gandhi BM, Rao AL, Rao JV. UPLC-MS/MS method for determination of sofosbuvir in human plasma. Ann Pharm Fr 2017;75:257-66.
78. Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, et al. Preclinical characterization of the novel hepatitis C Virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother 2014;58:647-53.
79. Ayisi NK. High-performance liquid chromatographlc analysis of (E)- 5-(2-bromovinyl)-Z’deoxyuridine and its metabolites in serum, urine and herpes simplex virus Type-l infected cells. J Chromatogr 1986;375: 423-30.
80. Reeuwijk HJ, Lingeman H, Tjaden UR, de Bruijn EA, Keizer HJ, van der Greef J. Bioanalysis of (E)-5-(2-bromovinyl)-2’-deoxyuridine. J Chromatogr 1988;428:93-102.
81. Peng XD, Tan ZR, Wu HZ, Zhou G, Guo CX, Pei Q, et al. LC-MS-MS quantitative determination of brivudine in human plasma and its application to pharmacokinetic studies. Chromatographia 2011;73:1089-95.
82. Dyade GK, Sawant RL. Simple bioanalytical quantification method for simultaneous estimation of simvastatin and ezetimibe in human plasma by reverse-phase high-performance liquid chromatography technique. Asian J Pharm Clin Res 2020;13:160-5.
83. Yin P, Lehmann R, Xu G. Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal Bioanal Chem 2015;407:4879-92.
84. Deglon J, Leuthold LA, Thomas A. Potential missing steps for a wide use of dried matrix spots in biomedical analysis. Bioanalysis 2015;7:2375-85.
85. Li W. Evaluation of plasma microsampling for dried plasma spots (DPS) in quantitative LC-MS/MS bio-analysis using ritonavir as a model compound. J Chromatogr B Analyt Technol Biomed Life Sci 2015;991:46-52.
86. Sen A. Metabolic phenotype of the healthy rodent model using in-vial extraction of dried serum, urine, and cerebrospinal fluid spots. Anal Chem 2013;85:7257-63.
87. Dong Y. A sensitive dilute-and-shoot approach for the simultaneous screening of 71 stimulants and 7 metabolites in human urine by LC-MS-MS with dynamic MRM. J Chromatogr Sci 2015;53:1528-35.
88. Cao Z, Kaleta E, Wang P. Simultaneous quantitation of 78 Drugs and metabolites in urine with a dilute-and-shoot LC-MS-MS assay. J Anal Toxicol 2015;39:335-46.
89. Rodin I. ‘Dilute-and-shoot’ RSLC-MS-MS method for fast detection of nerve and vesicant chemical warfare agent metabolites in urine. J Anal Toxicol 2015;39:69-74.
90. Kohler I, Schappler J, Rudaz J, Microextraction techniques combined with capillary electrophoresis in bio-analysis. Anal Bioanal Chem 2013;405:125-41.
91. Silva C. Microextraction by packed sorbent (MEPS) and solid-phase microextraction (SPME) as sample preparation procedures for the metabolomic profiling of urine. Metabolites 2014;4:71-97.
92. Bojko B. Low invasive in vivo tissue sampling for monitoring biomarkers and drugs during surgery. Lab Invest 2014;94:586-94.
93. Cudjoe E. Solid-phase microextraction: A complementary in vivo sampling method to microdialysis. Angew Chem Int Ed Engl 2013;52:12124-6.
94. Thulasiraman, V. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 2005;26:3561-71.
95. Staub A. Analysis of hemoglobin-based oxygen carriers by CE-UV/Vis and CE-ESITOF/MS. Electrophoresis 2010;31:1241-7.
96. Rezaee M. Determination of organic compounds in water using dispersive liquid-liquid microextraction. J Chromatogr A 2006;1116:1-9.
97. Zuloaga O. Dispersive liquid-liquid microextraction: Trends in the analysis of biological samples. Bioanalysis 2015;7:2211-25.
98. Li Y. Development of a efficient and sensitive dispersive liquid-liquid microextraction technique for extraction and preconcentration of 10 beta2-agonists in animal urine. PLoS One 2015;10:e0137194.
99. Kohler I. Dispersive liquid-liquid microextraction combined with capillary electrophoresis and time-of-flight mass spectrometry for urine analysis. J Pharm Biomed Anal 2013;73:82-9.
Statistics
41 Views | 60 Downloads
Citations
How to Cite
S, S., M. V, K. SABAPATHI S, and C. A. “BIOANALYSIS METHOD DEVELOPMENT AND VALIDATION OF SMALL MOLECULES IN PHARMACEUTICAL INDUSTRY: A BIOANALYST REVIEW POINT”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 3, Mar. 2021, pp. 49-55, doi:10.22159/ajpcr.2021.v14i3.40528.
Section
Review Article(s)